• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dupilumab in acquired perforating dermatosis: A potential new treatment.

作者信息

Alsebayel Musaed M, Alzaid Tariq, Alobaida Saud A

机构信息

Department of Dermatology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Department of Dermatopathology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

出版信息

JAAD Case Rep. 2022 Aug 11;28:34-36. doi: 10.1016/j.jdcr.2022.08.013. eCollection 2022 Oct.

DOI:10.1016/j.jdcr.2022.08.013
PMID:36097624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9463549/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec99/9463549/b488283129a3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec99/9463549/edc27e603728/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec99/9463549/b488283129a3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec99/9463549/edc27e603728/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec99/9463549/b488283129a3/gr1.jpg

相似文献

1
Dupilumab in acquired perforating dermatosis: A potential new treatment.度普利尤单抗治疗获得性穿通性皮肤病：一种潜在的新疗法。
JAAD Case Rep. 2022 Aug 11;28:34-36. doi: 10.1016/j.jdcr.2022.08.013. eCollection 2022 Oct.
2
Acquired Perforating Dermatosis and Dermatology Life Quality Index in Patients Receiving hemodialysis.接受血液透析患者的获得性穿通性皮肤病与皮肤病生活质量指数
Nefrologia (Engl Ed). 2024 Mar-Apr;44(2):251-255. doi: 10.1016/j.nefroe.2024.03.006. Epub 2024 Mar 29.
3
A clinicopathologic study of thirty cases of acquired perforating dermatosis in Korea.韩国30例获得性穿通性皮肤病的临床病理研究。
Ann Dermatol. 2014 Apr;26(2):162-71. doi: 10.5021/ad.2014.26.2.162. Epub 2014 Apr 30.
4
Effective treatment of uremic pruritus and acquired perforating dermatosis with amitriptyline.阿米替林有效治疗尿毒症性瘙痒和获得性穿通性皮肤病。
Australas J Dermatol. 2014 Aug;55(3):e54-7. doi: 10.1111/ajd.12026. Epub 2013 Feb 21.
5
Acquired perforating dermatosis: a report of 8 cases.获得性穿通性皮肤病：8例报告。
Actas Dermosifiliogr. 2014 Jul-Aug;105(6):e39-43. doi: 10.1016/j.ad.2013.09.014. Epub 2014 Jan 17.
6
Acquired perforating dermatosis in patients on peritoneal dialysis: a report of 3 cases.腹膜透析患者的获得性穿通性皮肤病：3例报告
AME Case Rep. 2023 Oct 12;7:46. doi: 10.21037/acr-23-9. eCollection 2023.
7
Clinical characteristics and prognosis of acquired perforating dermatosis: A case report.获得性穿通性皮肤病的临床特征与预后：一例报告
Exp Ther Med. 2020 Jun;19(6):3634-3640. doi: 10.3892/etm.2020.8651. Epub 2020 Apr 9.
8
Acquired perforating dermatosis: clinicopathological features in twenty-two cases.获得性穿通性皮肤病：22例临床病理特征
J Eur Acad Dermatol Venereol. 2006 Jul;20(6):679-88. doi: 10.1111/j.1468-3083.2006.01571.x.
9
[Acquired perforating dermatosis in the patient with chronic kidney disease – case report and literature review].[慢性肾脏病患者获得性穿通性皮肤病——病例报告及文献复习]
Przegl Lek. 2016;73(9):680-3.
10
Giant variant of acquired perforating dermatosis in a renal dialysis patient.一名肾透析患者的获得性穿通性皮肤病巨变体
JAAD Case Rep. 2017 Jan 31;3(1):42-44. doi: 10.1016/j.jdcr.2016.10.004. eCollection 2017 Jan.

引用本文的文献

1
Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation.度普利尤单抗可改善由 2 型炎症引起的获得性反应性穿孔性胶原病。
Front Immunol. 2023 Aug 10;14:1240262. doi: 10.3389/fimmu.2023.1240262. eCollection 2023.
2
Acquired perforating dermatosis: A clinicopathologic study, and the features of dermoscopy and reflective confocal microscopy of 37 cases.获得性穿孔性皮肤病：37 例的临床病理研究及皮肤镜和反射共聚焦显微镜特征。
Skin Res Technol. 2023 Jul;29(7):e13416. doi: 10.1111/srt.13416.
3
Perforating Gout: Expanding the Differential for Transepidermal Elimination.

本文引用的文献

1
Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD.度普利尤单抗可能是治疗伴有 AD 的获得性反应性穿孔性胶原病的一种替代选择。
Immun Inflamm Dis. 2022 Mar;10(3):e574. doi: 10.1002/iid3.574. Epub 2021 Dec 24.
2
Evaluation of clinicopathological and treatment characteristics of 80 patients with acquired perforating dermatosis.评价 80 例获得性穿孔性皮肤病患者的临床病理及治疗特点。
Dermatol Ther. 2020 Nov;33(6):e14465. doi: 10.1111/dth.14465. Epub 2020 Nov 5.
3
New and emerging treatments for inflammatory itch.
穿通性痛风：扩大经表皮消除的鉴别诊断范围
Dermatopathology (Basel). 2023 Jul 12;10(3):207-218. doi: 10.3390/dermatopathology10030029.
4
Dupilumab in Inflammatory Skin Diseases: A Systematic Review.度普利尤单抗治疗炎症性皮肤病：系统评价。
Biomolecules. 2023 Mar 31;13(4):634. doi: 10.3390/biom13040634.
新型和新兴的治疗炎症性瘙痒的方法。
Ann Allergy Asthma Immunol. 2021 Jan;126(1):13-20. doi: 10.1016/j.anai.2020.05.028. Epub 2020 Jun 1.
4
A review of dupilumab in the treatment of atopic diseases.度普利尤单抗治疗特应性疾病的研究综述。
Hum Vaccin Immunother. 2019;15(9):2129-2139. doi: 10.1080/21645515.2019.1582403. Epub 2019 Mar 27.
5
Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.度普利尤单抗治疗中重度特应性皮炎：系统评价和荟萃分析。
J Dermatol Sci. 2018 May;90(2):190-198. doi: 10.1016/j.jdermsci.2018.01.016. Epub 2018 Feb 20.
6
Acquired reactive perforating dermatosis.获得性反应性穿孔性皮肤病。
J Dtsch Dermatol Ges. 2013 Aug;11(8):723-9, 723-30. doi: 10.1111/ddg.12131. Epub 2013 May 29.
7
Up-regulation of transforming growth factor-beta3 and extracellular matrix proteins in acquired reactive perforating collagenosis.获得性反应性穿通性胶原病中转化生长因子-β3和细胞外基质蛋白的上调
J Am Acad Dermatol. 2009 Mar;60(3):463-9. doi: 10.1016/j.jaad.2008.06.006.
8
Acquired perforating dermatosis: clinicopathological features in twenty-two cases.获得性穿通性皮肤病：22例临床病理特征
J Eur Acad Dermatol Venereol. 2006 Jul;20(6):679-88. doi: 10.1111/j.1468-3083.2006.01571.x.
9
Acquired perforating dermatosis in a British dialysis population.英国透析人群中的获得性穿通性皮肤病
Br J Dermatol. 1996 Nov;135(5):671-7.